Evidence map›Paper›PMID 40814128›Full record

ReviewChinese medical journal2025

Cellular senescence in kidney diseases.

Xiaojie Wang, Yujia Li, Qingqing Chu, Hang Lv, Jing Li, Fan Yi

Abstract readReview
In one paragraph

Review in Chinese medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xiaojie WangDepartment of Pharmacology, School of Basic Medical Sciences, Shandong University, Jinan, Shandong 250012, China.
Yujia LiDepartment of Pharmacology, School of Basic Medical Sciences, Shandong University, Jinan, Shandong 250012, China.
Qingqing ChuDepartment of Pharmacology, School of Basic Medical Sciences, Shandong University, Jinan, Shandong 250012, China.
Hang LvDepartment of Pharmacology, School of Basic Medical Sciences, Shandong University, Jinan, Shandong 250012, China.
Jing LiDepartment of Pharmacology, School of Basic Medical Sciences, Shandong University, Jinan, Shandong 250012, China.
Fan YiDepartment of Pharmacology, School of Basic Medical Sciences, Shandong University, Jinan, Shandong 250012, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

abstractCellular senescence, stable cell cycle arrest that can be triggered in normal cells in response to various intrinsic and extrinsic stressors, has been highlighted as one of the most important mechanisms involved in kidney diseases. It not only serves as a fundamental biological process promoting normal organogenesis and successful wound repair but also contributes to organ dysfunction, tissue fibrosis, and the generalized aging phenotype. Moreover, senescent cells exhibit reduced regenerative capacity, which impairs renal function recovery from injuries. Importantly, senescent cells are involved in immune regulation via secreting a diverse array of proinflammatory and profibrotic factors known as senescence-associated secretory phenotype (SASP) with autocrine, paracrine, and endocrine activities. Thus, eliminating detrimental senescent cells or inhibiting SASP production holds great promise for developing innovative therapeutic strategies for kidney diseases. In this review, we summarize the current knowledge of the intricate mechanisms and hallmarks of cellular senescence in kidney diseases and emphasize novel therapeutic targets, including epigenetic regulators, G protein-coupled receptors, and lysosome-related proteins. Particularly, we highlight the recently identified senotherapeutics, which provide new therapeutic strategies for treating kidney diseases.

Indexed as

Cellular SenescenceKidney DiseasesAnimalsEpigenesis, GeneticHumansSenescence-Associated Secretory PhenotypeCellular senescenceG protein-coupled receptorsHistone deacetylasesInflammationKidney diseases

Identifiers

PMID40814128
PMCPMC12453375

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.